

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 7/23/1957
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Antimicrobial Susceptibility, AFB/Mycobacteria

ARUP test code 0060217

Collected: 00/00/0000 00:00 MT
Started: 00/00/0000 00:00 MT

Source: **Respiratory**

Body Site: **Sputum**

Free Text Sources:

Final Report

Mycobacterium intracellulare
Organism identified by client

Susceptibility Results

Organism: **Mycobacterium intracellulare**

Amikacin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 8
Clarithromycin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 0.5
Linezolid	Interpretation: SUSCEPTIBLE MIC (ug/mL): 8
Moxifloxacin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 1

S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate,
SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-171-401360
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 2 | Printed: 7/12/2024 3:03:31 PM
4848

Interpretive Information

Interpretation: **SEE NOTE**

For Mycobacterium avium-intracellulare complex, CLSI recommends testing and reporting clarithromycin, moxifloxacin, amikacin and linezolid. The reported amikacin interpretation is for IV; if using amikacin (liposomal, inhaled), the MIC interpretive breakpoints are <=64 ug/mL Susceptible, >=128 ug/mL Resistant. The in vivo effectiveness of Moxifloxacin and Linezolid for MAC disease is unproven. Ethambutol, rifampin and rifabutin MIC results are not reported because MIC values are not predictive of clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology. Interpret results in conjunction with clinical presentation. Test developed and characteristics determined by ARUP Laboratories. See compliance Statement B: aruplab.com/CS.

Interpretive Results

INTERPRETIVE INFORMATION: Susceptibility, Mycobacteria

Units = ug/mL

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Antimicrobial Susceptibility, AFB/Mycobacteria	24-171-401360	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: